Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameVerastem Inc.
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









